DANONE (BSN.DE) Stock Fundamental Analysis
Europe - FRA:BSN - FR0000120644 - Common Stock
78.54 EUR
-1.08 (-1.36%)
Taking everything into account, BSN scores 5 out of 10 in our fundamental rating. BSN was compared to 55 industry peers in the Food Products industry. BSN scores excellent on profitability, but there are some minor concerns on its financial health. BSN is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
BSN had positive earnings in the past year.
BSN had a positive operating cash flow in the past year.
In the past 5 years BSN has always been profitable.
Each year in the past 5 years BSN had a positive operating cash flow.
1.2 Ratios
With a decent Return On Assets value of 4.20%, BSN is doing good in the industry, outperforming 63.16% of the companies in the same industry.
BSN has a better Return On Equity (11.59%) than 64.91% of its industry peers.
With a decent Return On Invested Capital value of 6.83%, BSN is doing good in the industry, outperforming 63.16% of the companies in the same industry.
BSN had an Average Return On Invested Capital over the past 3 years of 6.38%. This is in line with the industry average of 6.93%.
The 3 year average ROIC (6.38%) for BSN is below the current ROIC(6.83%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.2% | ||
| ROE | 11.59% | ||
| ROIC | 6.83% |
ROA(3y)2.83%
ROA(5y)3.44%
ROE(3y)7.34%
ROE(5y)9%
ROIC(3y)6.38%
ROIC(5y)6.21%
1.3 Margins
BSN has a Profit Margin of 6.72%. This is in the better half of the industry: BSN outperforms 73.68% of its industry peers.
In the last couple of years the Profit Margin of BSN has remained more or less at the same level.
With a decent Operating Margin value of 13.25%, BSN is doing good in the industry, outperforming 78.95% of the companies in the same industry.
In the last couple of years the Operating Margin of BSN has declined.
BSN has a better Gross Margin (50.47%) than 77.19% of its industry peers.
In the last couple of years the Gross Margin of BSN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.25% | ||
| PM (TTM) | 6.72% | ||
| GM | 50.47% |
OM growth 3Y-1.81%
OM growth 5Y-3.08%
PM growth 3Y-1.94%
PM growth 5Y-0.54%
GM growth 3Y1.56%
GM growth 5Y0.26%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so BSN is still creating some value.
The number of shares outstanding for BSN has been increased compared to 1 year ago.
BSN has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, BSN has an improved debt to assets ratio.
2.2 Solvency
BSN has an Altman-Z score of 2.57. This is not the best score and indicates that BSN is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of BSN (2.57) is better than 64.91% of its industry peers.
The Debt to FCF ratio of BSN is 5.07, which is a neutral value as it means it would take BSN, 5.07 years of fcf income to pay off all of its debts.
With a decent Debt to FCF ratio value of 5.07, BSN is doing good in the industry, outperforming 70.18% of the companies in the same industry.
BSN has a Debt/Equity ratio of 0.83. This is a neutral value indicating BSN is somewhat dependend on debt financing.
BSN's Debt to Equity ratio of 0.83 is on the low side compared to the rest of the industry. BSN is outperformed by 71.93% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.83 | ||
| Debt/FCF | 5.07 | ||
| Altman-Z | 2.57 |
ROIC/WACC1.05
WACC6.53%
2.3 Liquidity
A Current Ratio of 0.95 indicates that BSN may have some problems paying its short term obligations.
The Current ratio of BSN (0.95) is worse than 77.19% of its industry peers.
A Quick Ratio of 0.78 indicates that BSN may have some problems paying its short term obligations.
BSN has a Quick ratio (0.78) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.95 | ||
| Quick Ratio | 0.78 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 4.47% over the past year.
The Earnings Per Share has been decreasing by -1.17% on average over the past years.
The Revenue has been growing slightly by 0.54% in the past year.
BSN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.60% yearly.
EPS 1Y (TTM)4.47%
EPS 3Y3.12%
EPS 5Y-1.17%
EPS Q2Q%6.11%
Revenue 1Y (TTM)0.54%
Revenue growth 3Y4.08%
Revenue growth 5Y1.6%
Sales Q2Q%-0.15%
3.2 Future
BSN is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.39% yearly.
Based on estimates for the next years, BSN will show a small growth in Revenue. The Revenue will grow by 3.15% on average per year.
EPS Next Y8%
EPS Next 2Y7.34%
EPS Next 3Y7.61%
EPS Next 5Y6.39%
Revenue Next Year0.68%
Revenue Next 2Y1.86%
Revenue Next 3Y2.53%
Revenue Next 5Y3.15%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 21.00, the valuation of BSN can be described as rather expensive.
BSN's Price/Earnings is on the same level as the industry average.
BSN's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 25.89.
BSN is valuated rather expensively with a Price/Forward Earnings ratio of 18.78.
64.91% of the companies in the same industry are cheaper than BSN, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 34.59, BSN is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21 | ||
| Fwd PE | 18.78 |
4.2 Price Multiples
BSN's Enterprise Value to EBITDA ratio is in line with the industry average.
BSN's Price/Free Cash Flow is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 18.65 | ||
| EV/EBITDA | 11.27 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
BSN has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)2.63
PEG (5Y)N/A
EPS Next 2Y7.34%
EPS Next 3Y7.61%
5. Dividend
5.1 Amount
BSN has a Yearly Dividend Yield of 2.70%.
BSN's Dividend Yield is a higher than the industry average which is at 3.31.
Compared to an average S&P500 Dividend Yield of 2.44, BSN has a dividend comparable with the average S&P500 company.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.7% |
5.2 History
The dividend of BSN has a limited annual growth rate of 1.58%.
Dividend Growth(5Y)1.58%
Div Incr Years3
Div Non Decr Years4
5.3 Sustainability
74.99% of the earnings are spent on dividend by BSN. This is not a sustainable payout ratio.
BSN's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP74.99%
EPS Next 2Y7.34%
EPS Next 3Y7.61%
FRA:BSN (11/14/2025, 7:00:00 PM)
78.54
-1.08 (-1.36%)
Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryFood Products
Earnings (Last)
Earnings (Next)
Inst Owners55.49%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap53.52B
Revenue(TTM)27.36B
Net Income(TTM)1.84B
Analysts74.84
Price Target79.13 (0.75%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.7% |
Yearly Dividend2.1
Dividend Growth(5Y)1.58%
DP74.99%
Div Incr Years3
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.6%
PT rev (3m)2.46%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0.33%
EPS NY rev (3m)0.04%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.14%
Revenue NY rev (3m)-0.12%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21 | ||
| Fwd PE | 18.78 | ||
| P/S | 1.96 | ||
| P/FCF | 18.65 | ||
| P/OCF | 13.91 | ||
| P/B | 3.37 | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.27 |
EPS(TTM)3.74
EY4.76%
EPS(NY)4.18
Fwd EY5.33%
FCF(TTM)4.21
FCFY5.36%
OCF(TTM)5.64
OCFY7.19%
SpS40.15
BVpS23.28
TBVpS-9.5
PEG (NY)2.63
PEG (5Y)N/A
Graham Number44.26
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.2% | ||
| ROE | 11.59% | ||
| ROCE | 12.02% | ||
| ROIC | 6.83% | ||
| ROICexc | 8.36% | ||
| ROICexgc | 50.58% | ||
| OM | 13.25% | ||
| PM (TTM) | 6.72% | ||
| GM | 50.47% | ||
| FCFM | 10.49% |
ROA(3y)2.83%
ROA(5y)3.44%
ROE(3y)7.34%
ROE(5y)9%
ROIC(3y)6.38%
ROIC(5y)6.21%
ROICexc(3y)7.67%
ROICexc(5y)7.39%
ROICexgc(3y)52.44%
ROICexgc(5y)45.6%
ROCE(3y)10.98%
ROCE(5y)10.58%
ROICexgc growth 3Y19.7%
ROICexgc growth 5Y13.36%
ROICexc growth 3Y4.65%
ROICexc growth 5Y1.26%
OM growth 3Y-1.81%
OM growth 5Y-3.08%
PM growth 3Y-1.94%
PM growth 5Y-0.54%
GM growth 3Y1.56%
GM growth 5Y0.26%
F-Score8
Asset Turnover0.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.83 | ||
| Debt/FCF | 5.07 | ||
| Debt/EBITDA | 2.71 | ||
| Cap/Depr | 77.72% | ||
| Cap/Sales | 3.57% | ||
| Interest Coverage | 23.53 | ||
| Cash Conversion | 78.8% | ||
| Profit Quality | 156.01% | ||
| Current Ratio | 0.95 | ||
| Quick Ratio | 0.78 | ||
| Altman-Z | 2.57 |
F-Score8
WACC6.53%
ROIC/WACC1.05
Cap/Depr(3y)59.49%
Cap/Depr(5y)65.43%
Cap/Sales(3y)3.2%
Cap/Sales(5y)3.59%
Profit Quality(3y)220.86%
Profit Quality(5y)178.79%
High Growth Momentum
Growth
EPS 1Y (TTM)4.47%
EPS 3Y3.12%
EPS 5Y-1.17%
EPS Q2Q%6.11%
EPS Next Y8%
EPS Next 2Y7.34%
EPS Next 3Y7.61%
EPS Next 5Y6.39%
Revenue 1Y (TTM)0.54%
Revenue growth 3Y4.08%
Revenue growth 5Y1.6%
Sales Q2Q%-0.15%
Revenue Next Year0.68%
Revenue Next 2Y1.86%
Revenue Next 3Y2.53%
Revenue Next 5Y3.15%
EBIT growth 1Y3.81%
EBIT growth 3Y2.2%
EBIT growth 5Y-1.53%
EBIT Next Year35.38%
EBIT Next 3Y14.38%
EBIT Next 5Y10.92%
FCF growth 1Y12.42%
FCF growth 3Y6.14%
FCF growth 5Y3.12%
OCF growth 1Y12.55%
OCF growth 3Y3.31%
OCF growth 5Y2.15%
DANONE / BSN.DE FAQ
What is the fundamental rating for BSN stock?
ChartMill assigns a fundamental rating of 5 / 10 to BSN.DE.
What is the valuation status of DANONE (BSN.DE) stock?
ChartMill assigns a valuation rating of 2 / 10 to DANONE (BSN.DE). This can be considered as Overvalued.
How profitable is DANONE (BSN.DE) stock?
DANONE (BSN.DE) has a profitability rating of 7 / 10.
What are the PE and PB ratios of DANONE (BSN.DE) stock?
The Price/Earnings (PE) ratio for DANONE (BSN.DE) is 21 and the Price/Book (PB) ratio is 3.37.
Can you provide the expected EPS growth for BSN stock?
The Earnings per Share (EPS) of DANONE (BSN.DE) is expected to grow by 8% in the next year.